3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gastrointestinal
1
Endocrine
1
Conditions
Colorectal Neoplasms
17
Neoplasms
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Carcinoma, Hepatocellular
10
Stomach Neoplasms
9
Colonic Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Thyroid Neoplasms
7
Pancreatic Neoplasms
7
Cholangiocarcinoma
7
Breast Neoplasms
7
Esophageal Neoplasms
6
Sarcoma
5
Neuroendocrine Tumors
5
Lung Neoplasms
5
Head and Neck Neoplasms
5
Gastrointestinal Neoplasms
5
Biliary Tract Neoplasms
5
Adenocarcinoma
5
Thyroid Diseases
4
Thyroid Cancer, Papillary
4
Thoracic Neoplasms
4
Respiratory Tract Neoplasms
4
Respiratory Tract Diseases
4
Neoplasms by Site
4
Lung Diseases
4
Liver Neoplasms
4
Endocrine System Diseases
4
Endocrine Gland Neoplasms
4
Carcinoma, Bronchogenic
4
Interventions
pralsetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Neoplasms, Glandular and Epithelial
×
Gastrointestinal
×
Clear all
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA